Josh Cohen (L) and Justin Klee, Amylyx co-CEOs
Amylyx's ALS drug gets a three-month PDUFA delay, setting up the pivotal decision for September
ALS patients in the US are going to have to wait a little bit longer to find out whether they’ll have a new treatment option …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
